(Total Views: 847)
Posted On: 01/31/2022 3:28:59 PM
Post# of 148887
First post, mainly to express an appreciation of the monitors of this board for creating a decent forum for discussion and sharing. I come from a medical background and am also grateful for the considerable infusion of insight from the likes of ohm20 and others which confirm for me how special this molecule is, sitting at the nexus of a multitude of inflammatory and immune-mediated processes. Equally startling to me is the paucity of side effects, which are the nemesis of so many pharmacological therapies.
A finance professor I had years ago said that true value always wins out in the end, so I continue to wait with the rest of us that know the value of what we own. I am amazed at the headwinds this company has faced, but they have persisted and to borrow a line from Calvin Coolidge, persistence alone is omnipotent. The incessant waves of short dumps have been met with buying by myself and others that are clear on the value, so ownership is also moving inexorably toward holders with conviction. I believe the radio silence portends a binary event which more likely than not will accrue to the benefit of those who see the value in a platform molecule and I am not the least bit surprised this is taking time…this is not a one trick pony but a diamond that has to be looked at from many different angles to properly inform any discussion of partnership or buyout.
As I wait in the silence for news I am hopeful Brazil answers out of left field and is able to help finally get this drug into the hands of clinicians, which is way overdue. I share the sentiment of many here that at this point it is beyond money and is a moral imperative if we can take death off the table for critical covid19. The failure of regulatory agencies to act like we are on a war footing with the virus, the catatonic (or adversarial) response to Leronlimab with no safety signal but repeated demonstration of impact has contributed to the hollowing out of the ranks of seasoned health care providers who are leaving the system in large numbers from exhaustion. Like loved ones that have been lost in the pandemic, they are not so readily replaced.
A finance professor I had years ago said that true value always wins out in the end, so I continue to wait with the rest of us that know the value of what we own. I am amazed at the headwinds this company has faced, but they have persisted and to borrow a line from Calvin Coolidge, persistence alone is omnipotent. The incessant waves of short dumps have been met with buying by myself and others that are clear on the value, so ownership is also moving inexorably toward holders with conviction. I believe the radio silence portends a binary event which more likely than not will accrue to the benefit of those who see the value in a platform molecule and I am not the least bit surprised this is taking time…this is not a one trick pony but a diamond that has to be looked at from many different angles to properly inform any discussion of partnership or buyout.
As I wait in the silence for news I am hopeful Brazil answers out of left field and is able to help finally get this drug into the hands of clinicians, which is way overdue. I share the sentiment of many here that at this point it is beyond money and is a moral imperative if we can take death off the table for critical covid19. The failure of regulatory agencies to act like we are on a war footing with the virus, the catatonic (or adversarial) response to Leronlimab with no safety signal but repeated demonstration of impact has contributed to the hollowing out of the ranks of seasoned health care providers who are leaving the system in large numbers from exhaustion. Like loved ones that have been lost in the pandemic, they are not so readily replaced.
(32)
(0)Scroll down for more posts ▼
